Review Open access

Modern therapeutic approaches in cholangiocarcinoma: A narrative review of key biomarkers and clinical trials

Augusto Almeida Joao Manzi Camila Hoff H. Kadri Alan Livingstone A. Gleisner E. B. Toegel R. Schulick P. Hoff Rodrigo Vianna Phillipe Abreu

Aug 2026 · Translational Oncology · Vol 72 · 1 citation · 180 references

Medicine

TL;DR

Current FDA-approved treatments for CCA include therapies targeting HER2, IDH1, FGFR2, and other key biomarkers, including therapies targeting HER2, IDH1, FGFR2, and other key biomarkers.

Abstract

Highlights • Cholangiocarcinoma (CCA) presents a significant clinical challenge with varied subtypes, each requiring tailored treatments.• Early diagnosis of CCA is difficult, leading to poor survival rates, particularly in advanced stages.• Precision medicine is advancing CCA management through targeted therapies based on specific molecular aberrations.• Recent FDA-approved treatments for CCA include therapies targeting HER2, IDH1, FGFR2, and other key biomarkers.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Review Sep 2026

Pancreatic ductal adenocarcinoma: Clinical trials to watch.

The treatment of PDAC is transitioning from uniform cytotoxic chemotherapy toward precision strategies guided by molecular identity and disease stage. RAS and PARP inhibitors and personalized neoantigen vaccination have created new options across metastatic and resectable disease. Chemotherapy timing relative to surger...

V. P. Groot, I. Molenaar, G. Cirkel et al. · i Medicina · 0 citations

Review Open access Aug 2026

Beyond a single disease: review of rare histological subtypes of triple-negative breast cancer with implications for prognosis and treatment

Triple-negative breast cancer (TNBC) is commonly approached as a single clinical entity despite marked biological heterogeneity. A subset of cases corresponds to rare histologic subtypes that display distinct molecular drivers, immune microenvironments, and clinical behavior. In this Review, we summarize the clinicop...

M. Gouveia, R. Bonadio, R. Barroso-Sousa et al. · npj Breast Cancer · 0 citations

Review Open access 2026

Cholangiocarcinoma in 2026: Pathophysiology, Diagnostic Advances, and Evolving Therapeutic Landscape—A Narrative Review

Cholangiocarcinoma (CCA) is a heterogeneous malignancy of the biliary epithelium, classified into intrahepatic, perihilar, and distal subtypes with distinct molecular signatures, risk factor profiles, and clinical behavior. This narrative review synthesizes current understanding of CCA pathophysiology, established and...

Elmukhtar Habas, Aml Habas, Amnna Ali Rayani et al. · Yemen Journal of Medicine · 0 citations

Open access Sep 2026

Comprehensive In Silico Analysis Identifies MSTO1 and LIG1 as Candidate Biomarkers With Diagnostic and Prognostic Relevance in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and remains a major cause of cancer‐related mortality worldwide. Its poor clinical outcomes are largely attributed to late‐stage diagnosis and the limited accuracy of currently available diagnostic and prognostic biomarkers. Therefore, identifyi...

Jana Hamad, Hussein Fayyad-Kazan, F. Abdel-Sater · Cancer Reports · 0 citations

Review Oct 2026

Emerging Platform Trials for the Treatment of Newly Diagnosed and Recurrent Glioblastoma.

Glioblastoma (GBM) remains highly morbid despite maximal safe resection, radiotherapy, and chemotherapy, prompting the expansion of clinical investigation. This review examines 4 emerging therapeutic strategies for newly diagnosed and recurrent GBM that address major biological barriers to treatment: tumor immunosuppre...

Deveney Franklin, D. Higgins · Hematology/Oncology Clinics... · 0 citations

Editorial Sep 2026

Editorial: Tumor microenvironment and personalized therapy of gastrointestinal cancer Ⅱ

, and esophageal cancers, addressing this challenge from complementary clinical and translational perspectives. The contributions highlight three interconnected dimensions of individualized cancer care: the role of systemic inflammatory, nutritional, and body-composition parameters in perioperative and postoperative ri...

Xin-Xin Wang, J. Tang, Shuang Yang et al. · Frontiers in Medicine · 0 citations